You are here: Industry Insights > CVnCoV

News List

CureVac, Rentschler Ramp up COVID Vax Production contractpharma
February 02, 2021
CureVac N.V. and Rentschler Biopharma SE, a global CDMO for biopharmaceuticals, initiated the set-up of manufacturing capabilities for CureVac´s COVID-19 vaccine, CVnCoV.
CureVac and Bayer Join Forces contractpharma
January 08, 2021
Bayer has signed a collaboration and services agreement with CureVac N.V., a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA).
CureVac initiates Phase IIb/III trial of Covid-19 vaccine candidate pharmaceutical-technology
December 16, 2020
German company CureVac has enrolled the first participant in the pivotal Phase IIb/III HERALD study to evaluate the safety and efficacy of its mRNA vaccine candidate, CVnCoV, against Covid-19.
CureVac and Wacker Sign Contract for Manufacturing of Covid-19 Vaccine Candidate contractpharma
November 25, 2020
Manufacturing at Wacker’s biotech site in Amsterdam is scheduled to start in the first half of 2021.
CureVac to Ramp Up Mfg. of COVID-19 Vax Candidate CVnCoV contractpharma
November 18, 2020
Will partner with CDMOs to increase manufacturing capacities for CVnCoV to up to 300 million doses in 2021 and up to 600 million doses in 2022.
CVnCoV COVID-19 vaccine safely elicits immune response in Phase I testing europeanpharmaceuticalreview
November 06, 2020
The interim Phase I data suggests CVnCoV can safely induce a neutralising antibody response similar to that of convalescent COVID-19 patients with two 12μg vaccine doses.
CureVac recieves €75 million loan for vaccine development and manufacturing expansion europeanpharmaceuticalreview
July 09, 2020
The European Investment Bank (EIB) will provide three €25 million instalments to support CureVac’s vaccine development and expansion to mRNA production facilities.

Previous page 1 2 Next page